

Minutes of the NBC-R meeting held on 07-01-2025

The National Bioethics Committee for Research (NBC-R) zoom meeting was held on January 7th, 2025. The following members of NBC-R attended the meeting:

1. Prof. Dr. Saima Pervaiz Iqbal	Chairperson
2. Prof. Dr. Jamshed Akhtar	Member
3. Prof. Dr. Munir Saleemi	Member
4. Prof. Dr. Marie Andrades	Member
5. Prof. Dr. Saqib Mehmood	Member
6. Dr. Farkhanda Ghafoor	Member
7. Ms. Tayyaba Rahat	National Coordinator NBC-R
8. Mr. Waryal Ali Daheri	LDC (NBC-R-Secretariat)

The following projects reviewed / discussed:

Title: **Serum Sampling of Dog-Bite Victims in Karachi, Pakistan, to Investigate the Pre- and Post-RABV Treatment Immune Response".**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1194	Dr. Naseem Salahuddin, The Indus Hospital, Opposite Darussalam Society, Korangi Crossing, Karachi	<ul style="list-style-type: none">• Please specify which anti-rabies vaccine is being tested?• The proposal claims that PCR-based diagnostic methodologies for rabies are currently unavailable for assessing active viral infections. However, this is contrary to the existing literature. For instance, the LN34 Pan-Lyssavirus RT-qPCR assay has been shown to demonstrate 100% sensitivity and 98% specificity outperforming traditional methods such as the direct fluorescent antibody test (dFAT). The proposal should acknowledge the availability and efficacy of such assays and clearly articulate whether this study seeks to validate or integrate these techniques into the local diagnostic framework.• Which cytokines are being measured? Can any of these tests be done in Pakistan? If not, is there any capacity development in the pipeline?

Title: **Increasing Middle School Enrolment: Testing the Efficacy of Targeted Solutions in Locations with Unrestricted Middle-School Access/Middle School Transition study (DARE-MST).**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1195	Dr. Zainab Latif Oxford Policy Management, Pakistan Plot 271, St No.1, Sector I-9/3, Islamabad	<ul style="list-style-type: none">• Why in particular has district Khushaab been selected?• Has permission been taken from the school Principals or Education department for this study?• Please mention who is doing the school and class observation.• There is no mention of duration required for focus group sessions.• The proposal also states asking for contact numbers of students. Would that be culturally appropriate especially where girls are concerned?

Title: **Effect of maternal multiple micronutrient supplementation from preconception through lactation on child growth and development in rural Pakistan: A follow-up study..**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1196	Dr. Zulfiqar Bhutta Distinguished University Professor & Founding Director Institute for Global Health and Development , Aga Khan university University Stadium Road, Karachi.	<ul style="list-style-type: none">• Study Approved.

Next meeting:

The next zoom meeting will be held at 02:30 pm on 14th January, 2025. The following projects will be reviewed:

Projects will be discussed. NBCR-1197, NBCR-1198 & NBCR-1199

Minutes of the NBC-R meeting held on 14-01-2025

The National Bioethics Committee for Research (NBC-R) zoom meeting was held on January 14th, 2025. The following members of NBC-R attended the meeting:

9. Prof. Dr. Saima Pervaiz Iqbal	Chairperson
10. Prof. Dr. Jamshed Akhtar	Member
11. Prof. Dr. Munir Saleemi	Member
12. Prof. Dr. Saqib Mehmood	Member
13. Prof. Dr. Marie Andrades	Member
14. Dr. Farkhanda Ghafoor	Member
15. Prof. Dr. Amjad Mehboob	Member
16. Ms. Tayyaba Rahat	National Coordinator NBC-R
17. Ms. Ayesha Abid	Assistant (NBC-R-Secretariat)

The following projects reviewed / discussed:

Title: **Trial: Does Folinic Acid Supplementation Affect the Outcome in Neonate with Hypoxic Ischemic Encephalopathy?**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1197	Dr. Bushra Fatima, Department of Neonatology, University of Child Health Sciences and Children's Hospital , Lahore	<ul style="list-style-type: none"> • Please give a rationale as to why this study needs to be done in Pakistan only? Why can it not be done in the UK as well as hypoxic ischemic encephalopathy is prevalent there as well. • Please clarify the methodology of an RCT. How will randomization be done? This also needs to be reflected on the informed consent form, that one group will be given a placebo. • Will baseline folinic acid levels be conducted on all CSF samples? • How will Pakistan benefit by being involved in this study? Is there a mechanism of sharing the benefits if folinic acid is found to be useful? Will it be available to our population? • Who is paying for all the tests being conducted? • Is the site approved by DRAP? • The PI/co-PI is involved in sending CSF samples to the UK in previous studies. Have those studies been approved by NBC or any other ethical review body?

Title: **Development and Piloting of AI-based Digital Learning Platform for Immunization in Pakistan.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1198	Dr. Zahid Memon Department of Community Health Sciences Aga Khan University Karachi"	<ul style="list-style-type: none"> • Study Approved.

Title: **Trial: Prospective Performance Diagnostic Accuracy Study of a New Rapid Diagnostic Test (RDT) for the Detection of Antibodies to Hepatitis C Virus.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1199	Prof. Dr. Saleem Ahmed Khan National University of Medical Sciences, The Mall, Rawalpindi, Pakistan	<ul style="list-style-type: none">• Please provide information about the local tool kit that is being tested for diagnostic accuracy. With what tool is it being compared against?• From where will samples be collected? Who are the volunteers for giving samples? Please specify.• What is the Data Management Agreement with the CRO that is involved? Why will they be storing samples and for what purpose?• Does this study really require a DSMB? This is more of a validation study.

Next meeting:

The next zoom meeting will be held at 02:30 pm on 21st January, 2025. The following projects will be reviewed:

Projects will be discussed. NBCR-1201, NBCR-1202 & NBCR-1203

Minutes of the NBC-R meeting held on 21-01-2025

The National Bioethics Committee for Research (NBC-R) zoom meeting was held on January 21st, 2025. The following members of NBC-R attended the meeting:

18. Prof. Dr. Saima Pervaiz Iqbal	Chairperson
19. Prof. Dr. Jamshed Akhtar	Member
20. Prof. Dr. Munir Saleemi	Member
21. Prof. Dr. Nazli Hossain	Member
22. Prof. Dr. Saqib Mehmood	Member
23. Prof. Dr. Marie Andrades	Member
24. Dr. Farkhanda Ghafoor	Member
25. Prof. Dr. Amjad Mehboob	Member
26. Ms. Tayyaba Rahat	National Coordinator NBC-R
27. Mr. Waryal Ali Daheri	LDC (NBC-R-Secretariat)

The following projects reviewed / discussed:

Title: **Trial: “Efficacy of vitamin D supplementation and metformin compared to metformin alone in infertile females with polycystic ovary syndrome: a randomized open label trial”.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1201	Dr. Rehana Rehman Dept of Biological & Biomedical Science Aga Khan University at Stadium Road Karachi	<ul style="list-style-type: none"> Why has this trial been presented to the NBC now when it was initiated several years ago? Are the participants being tested for Vitamin D toxicity? Has it been reported in any of the cohorts? How will therapeutic misconception be addressed as these women would be desperate to get pregnant? Some of the questions are not culturally appropriate like "Have you received a suntan in the last 12 months?" How much blood is being drawn...5 ml or 10 ml? It should be specified in the informed consent form. Who is paying for the tests and ultrasound? This should be mentioned in the informed consent form.

Title: **Urban PHC Policy Analysis and Evidence Generation Mixed methods research to understand the gaps in policy and implementation.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1202	Dr. Hina Sharif SINA Health Education & Welfare Trust Plot No.1 D-21, Sector 30 Karachi.	<ul style="list-style-type: none"> Study Approved.

Title: **Genetic and Demographic Consequences of Consanguinity in A Large Population (GenPK).**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1203	Dr. Muhammad Ansar Dow University of Health Sciences, Karachi, Pakistan	<ul style="list-style-type: none"> This study needs to be specific in terms of its objectives. All genetic disorders cannot be encompassed into one project. If the local PI has a background in Ophthalmology then specific disorders should be targeted. There is no community engagement in this project. What benefits would our population gain by being involved in this study? There is an obvious lack of cultural

		<p>sensitivity and this may create more problems for the people being involved.</p> <ul style="list-style-type: none"> • Why can this study not be done in Pakistan? Our local Universities are developing genetic testing kits so that we need not send our human samples abroad. • The project mentions that in Switzerland the samples will be outsourced at the lowest price. Does this mean that funds have yet to be secured for this project? • There is no MTA. Approval from the IRB of DUHS is required.
--	--	---

Next meeting:

The next zoom meeting will be held at 02:30 pm on 28th January, 2025. The following projects will be reviewed:

Projects will be discussed. NBCR-1204, NBCR-1205 & NBCR-1206

Minutes of the NBC-R meeting held on 28-01-2025

The National Bioethics Committee for Research (NBC-R) zoom meeting was held on January 28th, 2025. The following members of NBC-R attended the meeting:

28. Prof. Dr. Jamshed Akhtar	Chair the Meeting
29. Prof. Dr. Munir Saleemi	Member
30. Dr. Farkhanda Ghafoor	Member
31. Dr. Sualeha Siddiq Shekhani	Member
32. Prof. Dr. Saima Pervaiz Iqbal	Chairperson (Observations sent on email)
33. Prof. Dr. Saqib Mehmood	Member (Observations sent on email)
34. Prof. Dr. Marie Andrades	Member (Regret to Join)
35. Ms. Tayyaba Rahat	National Coordinator NBC-R

The following projects reviewed / discussed:

Title: **Assessing the Quality of Primary Health Care (PHC) Services in the Public Sector in Pakistan.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1204	Dr. Naeem Majeed SPHERE Consulting 2-Justice Sardar Iqbal Rd, Gulberg 5, Lahore	<ul style="list-style-type: none"> • Lot of data already exist on the subject from Pakistan. What is the need of this data collection on same subject? What were the findings of previous studies and what this research is going to find? • All four provinces have different PHC set ups and SOPs. How such differences shall be addressed? • Direct observation at PHC is threatening. Will it be prearranged? It can be a huge issue if deception is created. Why staff will let outside researcher to observe them? This can lead to harm as well. • There is no document found that shows a permission by the relevant health department. • It is very convenient to assess PHC services in major cities but that leaves the rural areas most vulnerable. This does not seem appropriate. • Details related to KPK and Baluchistan are not found. • This appears to be an audit of the PHC which is the job of the relevant authorities. They are not on board. The outside researcher may be biased in reporting data while ignoring the resources that a government can provide? • How they plan to send research officers into a facility? How approval shall be taken from the relevant staff? Why should they allow the outside researchers who are collecting data for other institutions? • Data transfer to another funder from US is an issue not addressed. • AKU IRB approval is suggested. • What is the conflict of interest of the university who has outsourced the process to a CRO? • Who is going to monitor or have an oversight on this project. • How much time they are expected to spend in the PHC? • Data collection tools mentions putting names of the participants. This is not appropriate. • In maternal health data, male is also mentioned. • Verbal consent is not appropriate strategy. A formal consent form is suggested as part of study from all stakeholders.

		<ul style="list-style-type: none"> • 2.3 is not satisfactory. Only publication is a purpose mentioned in this section. • It is expected that there should be a clear statement mentioning that BGMF is actually the funder. • The time of interaction is mentioned as 10 - 15 minutes in ICF. This is not possible. • The ICF is too general. Different tasks are assigned to the team at PHC. It has to be relevant to their scope of work. Same applies to the patients.
--	--	--

Title: **Primary Research- Primary Health Care Learning Agenda (PLA) Understanding the role of PHC in scaling up Family Planning services in Pakistan.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1205	Dr. Wasim Mirza Contech International 2-G Model Town, Lahore, Pakistan	<ul style="list-style-type: none"> • BGMF is the actual funder. This must be mentioned in the ICF. • Why would any PHC allow the researchers from outside for this study? • There is no formal letter from concerned ministries / departments about the study and permission granted. • Many studies already done on the subject from Pakistan. What new is expected out of another data collection? • The client interviews require privacy and confidentiality and we hope the investigators are equipped to deal with such delicate questions with appropriate responses. • It seems that AKUH is now outsourcing its researches to CROs. What ethical oversight will the University be providing to ensure integrity and robustness of the research processes? • Data transfer to another funder from US is an issue not addressed. • AKU IRB approval is suggested.

Title: **Experiences of the CEI members and Researchers working together during a Global Health Research on Stillbirth Prevention and Bereavement Care: A grounded theory study in Sub-Saharan Africa and South Asia.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1206	Prof Nasim Chaudhry Pakistan Institute of Living and Learning Suite No. 201, 2nd Floor, The Plaza, Karachi	<ul style="list-style-type: none"> • More information is required about CEI. For how long it has been working, how many members are there? What are their ongoing agendas? • Country specific protocols are not present. • From where subjects shall be enrolled? Details are not found. If it is going to be a medical facility, then mention its name. Local IRB approval shall be needed. • What benefits are there for study participants? • Will obstetricians / gynecologist be involved in this? • What are the interests of funders and PI from outside Pakistan? • Is there a data transfer agreement available? • What shall be done when study is completed? • Do you have any framework in mind to facilitate psychological well-being of the participants?

Next meeting:

The next zoom meeting will be held at 02:30 pm on 4th February, 2025. The following projects will be reviewed:

Data Sharing document will be discussed.



Member Secretary NBC-R



Chairperson NBC-R

Minutes of the NBC-R meeting held on 04-02-2025

The National Bioethics Committee for Research (NBC-R) zoom meeting was held on February 4th, 2025. The following members of NBC-R attended the meeting:

1. Dr. Nighat Murad	Executive Director HRI
2. Prof. Dr. Saima Pervaiz Iqbal	Chairperson
3. Prof. Dr. Jamshed Akhtar	Member
4. Prof. Dr. Munir Saleemi	Member
5. Prof. Dr. Nazli Hossain	Member
6. Prof. Dr. Marie Andrades	Member
7. Prof. Dr. Saqib Mehmood	Member
8. Prof. Dr. Amjad Mehboob	Member
9. Prof. Dr. Sualeha Siddiq Shekhani	Member
10. Dr. Farkhanda Ghafoor	Member
11. Dr. Faiza Bashir	Focal Person NBC-R
12. Ms. Tayyaba Rahat	National Coordinator NBC-R
13. Miss. Ayesha Abid	Assistant (NBC-R-Secretariat)
14. Mr. Waryal Ali Daheri	LDC (NBC-R-Secretariat)

Document of the Data Sharing discussed:

Next meeting:

The next zoom meeting will be held at 02:30 pm on 11th February, 2025. The following projects will be reviewed:

Minutes of the NBC-R meeting held on 11-02-2025

The National Bioethics Committee for Research (NBC-R) zoom meeting was held on February 11th, 2025. The following members of NBC-R attended the meeting:

1. Prof. Dr. Saima Pervaiz Iqbal	Chairperson
2. Prof. Dr. Jamshed Akhtar	Member
3. Prof. Dr. Munir Saleemi	Member
4. Prof. Dr. Nazli Hossain	Member
5. Prof. Dr. Saqib Mehmood	Member
6. Prof. Dr. Marie Andrades	Member
7. Dr. Farkhanda Ghafoor	Member
8. Dr. Sualeha Siddiq Shekhani	Member
9. Ms. Tayyaba Rahat	National Coordinator NBC-R
10. Miss. Ayesha Abid	Assistant (NBC-R Secretariat)

The following projects reviewed / discussed:

Title: **LU-177 BASED SYNOVECTOMY IN THE MANAGEMENT OF CHRONIC INFLAMMATORY JOINT DISEASES..**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1129	DR. Aakif Ullah Khan Director & Chief Medical Officer, Institute of Radiotherapy and Nuclear Medicine (IRNUM), Peshawar, Pakistan	<ul style="list-style-type: none"> • Rationale: This portion includes why this study needs to be done. It has to be for a particular joint problem and not all chronic conditions as mentioned in the proposal. How will this new therapy enhance scientific knowledge and improve patient outcomes? • Objective: Please mention what clinical end points the PI is determining to prove. Which subsets of patients are these? • Methodology: As far as we could gather, this is a clinical trial. It has to be compared with a standard of care. What is the standard of care? How will subjects be recruited? How will informed consent be administered? What of the subject refuses? How will that affect his/her care? Who are the other investigators in this research? • We suggest the PI to attend a workshop or collaborate with an experienced researcher to get clarity on the science of this study.

Title: **GLOBAL COLLABORATIVE FOR CHANGING DIABETES IN CHILDREN GLOBAL COHORT STUDY FOR TYPE 1 DIABETES.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1207	Prof. Abdul Basit Health Promotion Foundation Suit # 102, 1st Floor, Al-Ameera Center, Near Passport Office, Saddar, Karachi-Pakistan	<ul style="list-style-type: none"> • It is our understanding that the PI is no longer in BIDE. What is the affiliation of the PI? The IRB approval should be from that center. • Please identify the co-PIs who are collaborating in this project and from which institutions along with their support letters. • Why can this study not be done in the big cities like Karachi where the patient pool would be easier to collect? • Is there any pharmaceutical funding involved? • What is the Data Transfer Agreement in place? • We would like to see the country specific protocol for this study.

Title: **CO-ADMINISTRATION OF MULTIPLE MICRONUTRIENT AND CALCIUM SUPPLEMENTS FOR MATERNAL AND NEWBORN HEMOGLOBIN AND IRON STATUS.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1208	Dr. Sarah Saleem Department of Community Health Sciences Aga Khan University National Stadium Road Karachi	<ul style="list-style-type: none"> What will be options for women whose hemoglobin do not show any rise with MMNS? The investigators assume there is similarity between population of Burkino Faso and Thatta? How can this be justified? We see a lot of patients from the area with stained teeth, addicted to betel nut and gutka, there is no provision in the study, or they will be ineligible? Investigators should write explicitly whether they will store biospecimen or not? If yes, then there should be MTA for it. WHO is already providing this supplement to women in powder form, for women living in coastal belt?

Next meeting:

The next zoom meeting will be held at 02:30 pm on 18th February, 2025. The following projects will be reviewed:

NBCR-1209, NBCR-1210 and NBCR-1211.

Minutes of the NBC-R meeting held on 18-02-2025

The National Bioethics Committee for Research (NBC-R) zoom meeting was held on February 18th, 2025. The following members of NBC-R attended the meeting:

1. Prof. Dr. Jamshed Akhtar	Chair the Meeting
2. Prof. Dr. Munir Saleemi	Member
3. Prof. Dr. Nazli Hossain	Member
4. Prof. Dr. Amjad Mehboob	Member
5. Prof. Dr. Sualeha Siddiq Shekhani	Member (Sent comments on email)
6. Ms. Tayyaba Rahat	National Coordinator NBC-R
7. Miss. Ayesha Abid	Assistant (NBC-R Secretariat)

Regrets were sent by Dr. Farkhanda Ghafoor, Dr. Saima Parvaiz Iqbal and Dr. Saqib Mehmood

The following projects reviewed / discussed:

Title: **CARDIP FOLLOW UP STUDY: ASSESSING THE CARDIOVASCULAR DISEASE RISK FACTORS IN FOUR PROVINCES OF PAKISTAN.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1209	Dr. Syed Abbas Raza National Hospital and National Medical Center DHA Lahore	<ul style="list-style-type: none"> A pharmaceutical company is a sponsor. Is their conflict of interest? Why the study design is written as trial? A clarification is needed as it is an observational study. It has a retrospective arm that was conducted earlier as a cross sectional study and is published in JPMA. Provide previous NBC approval letter. Also provide informed consent for that study. It would be of interest to note if it contained the information that they shall be

		<p>contacted in future as well and their data will be re visited.</p> <ul style="list-style-type: none"> • AE and SAE reporting is meant for a trial. What are these? How it relates to this follow up study? • The monitoring of this study is for what purpose? • In what capacity Mr. Syed Abbas is sponsor of the study? This is funded by the Highnoon company? • Why data is the property of the funder? • IRB approval letters are required from other institutions and consent of the GPs. • List all the tests that shall be done and who will pay for it? Echocardiography is an important test, will it be included. • How PI has decided to finally include a number nearly 350 of the total subjects enrolled previously. • The present study does not include the previous investigators. How it will be ensured that same subjects are enrolled. • The budget does not include the costs for tests which is mentioned in the proposal that it will be covered by the study sponsor. • The name of the study is misleading since this is not a trial but rather a cross-sectional study. • A general physician can also be a consultant- this is vague in the questionnaire • There is a mention of an agreement but it is not clear.
--	--	---

Title: **Trial: MULTI-CENTER, RANDOMIZED, DOUBLE BLIND AND PLACEBO CONTROLLED CLINICAL TRIAL ON THE EFFICACY AND SAFETY OF JINHUA QINGGAN (JHQQ) GRANULES FOR THE TREATMENT OF ACUTE UPPER RESPIRATORY INFECTION (WIND-HEAT PATTERN).**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1210	<p>Prof. Dr. M. Raza Shah Center for Bioequivalence Studies and Clinical Research (CBSCR), International Center for Chemical and Biological Sciences (ICCBS), University of Karachi, Karachi</p>	<ul style="list-style-type: none"> • The inclusion of two CO PI is to be justified. One is simple MBBS and other is an anesthesia person. • The project is about a respiratory disease. • PI himself need to justify being PI which is a multicenter trial on a subject related to the clinical medicine. His expertise is bioequivalence and not involved in treatment of the patients. How funding is provided to the PI for a clinical study? • Provide DRAP approval certificate for the two hospitals that shall be the site for THIS TRIAL. COVID 19 related permission is no more valid. • Chinese IRB certificate translation in English is required. • Why competing interests of funding agency not matter? The product is about traditional Chinese medicine and is experimented of Pakistani and Jordanian people and simultaneously at China. It is of interest to know why there is a hurry in conducting this trial in Pakistan. • Data of usefulness mentioned is in context of influenza. Provide details of Phase I II and III trials conducted in China. • Why it is a placebo control trial? What is the standard of care?

		<ul style="list-style-type: none"> • What these granules re expected to do? Mode of action. • Age group is too wide. What if patient does not improve? • There is a mention of simulation in the project. This is not clear. • Why chest radiograph is needed for URTI? Is not done as a routine. • No insurance document found? • Data transfer agreement is not found. • DSMB has a psychiatrist as its member. He is not a substitute for a physician. Choose appropriate members. As it is trial, and health of the volunteer is of foremost importance. • Informed consent form must mention that the drug is not approved in Pakistan. Reference to year 2016 is deceptive. • Acetaminophen is also allowed in this trial in a particular situation. Does this mean failure of the intervention? This need clarity. • Large number of tests are part of this trial. Which phase of trial is being conducted? What is the need of these tests? These are not done usually in URTI patients. • How much blood shall be drawn? Where tests shall be performed? Will reports given to the study participants? • Amount to be paid to the participants is not mentioned. • Will patient remain hospitalized during the course of treatment? • AE SAE related document is not found. • What were the results of previous studies conducted particularly during Covid-19? • How the participants be recruited? This is unclear • The informed consent form is too long, and provides unnecessary details • In the proposal, the collaborating site included is Creek General Hospital and Pak General Hospital. Who are the PIs from there? ERC letters will also be required from these two institutions • The exclusion criteria is huge, who will be paying for all these tests? • Will the Co-PI from Southcity Hospital include his patients? • Batool General Hospital is a small clinic, who will be monitoring at Batool General Hospital, which basically provides maternity services.
--	--	---

Title: **IMAGING THE STRUCTURAL CORRELATES OF COGNITION IN PARKINSON'S DISEASE USING PORTABLE MRI.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1211	Dr. Kiran Aftab Lecturer, Department of Surgery, Aga Khan University, Karachi	<ul style="list-style-type: none"> • The PI is a lecturer in GS. How this may affect the conduct of study. • What are the conflict of interests of the UK institution where PI is probably enrolled? • Portable MRI findings need to be compared with regularly performed MRI. This is not found in this proposal. The portable MRI findings may not be reliable. Will that be added? If yes who will pay for it? • Why data will not be accessible to the patients? Will they be told the outcome? • What PI expect to gather from this interventional study that may help patients and their families plus volunteers? • What if new nervous system related condition is detected? • With whom this data shall be shared? Is any data sharing agreement done? • Some participants may still be incapacitated. How will informed consent be taken from them? There should be some form of surrogate decision-making which is acceptable in such participants • Is use portable MRI in other places indicated for same reason? • How data security will be ensured. This is an era of AI and patient's data is used for making algorithms.

Next meeting:

The next zoom meeting will be held at 02:30 pm on 25th February, 2025. The following projects will be reviewed:

NBCR-1212, NBCR-1213 and NBCR-1214.

Minutes of the NBC-R meeting held on 25-02-2025

The National Bioethics Committee for Research (NBC-R) zoom meeting was held on February 25th, 2025. The following members of NBC-R attended the meeting:

1. Prof. Dr. Jamshed Akhtar	Chair the Meeting
2. Prof. Dr. Munir Saleemi	Member
3. Prof. Dr. Nazli Hossain	Member
4. Prof. Dr. Saqib Mehmood	Member
5. Prof. Dr. Marie Andrades	Member
6. Prof. Dr. Amjad Mehboob	Member
7. Dr. Farkhanda Ghafoor	Member
8. Miss. Ayesha Abid	Assistant (NBC-R Secretariat)
9. Mr. Waryal Ali Daheri	LDC (NBC-R Secretariat)

The following projects reviewed / discussed:

Title: **Trial: COMPARATIVE EVALUATION OF KA6 X-RAY HANDHELD CAMERA VERSUS CONVENTIONAL X-RAY TO SUPPORT THE DIAGNOSIS OF PULMONARY TUBERCULOSIS (TB) THROUGH CHEST X-RAY.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1212	Dr. Muhammad Irfan Department of Medicine Aga Khan University Karachi	<ul style="list-style-type: none"> Budget is mentioned as provisional. It may be elaborated. There is no mention of how pregnant women shall be x rayed? Any protocol for shielding will be done. The software if included in processing the x rays then mention how confidentiality shall be addressed. What is the cost of this gadget? How it compares in cost effectiveness with already existing available x ray chest machine? Provide satisfaction survey form. Also share feedback forms to be used.

Title: **IDENTIFICATION OF PUTATIVELY DETRIMENTAL MUTATIONS ASSOCIATED WITH RECURRENT MISCARRIAGES IN PAKISTAN..**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1213	Dr. Farheena Iqbal Awan DNA Core Facility, Center for Applied Molecular Biology (CAMB), University of the Punjab Lahore	<ul style="list-style-type: none"> Are pharmacogenomics or epigenetic therapies available in Pakistan? That appears to be the actual benefit for the study participants. Other are just the risk factors and counseling can be done based upon available literature. Mention the details about the staff trained for this study. Ethical approval is still awaited from the universities. Mention name of the universities and share it with NBC. The informed consent is for blanket approval for all the future genetic studies. This is not appropriate. This is not mentioned in the ERC form. Elaborate which part of the research shall be done in Pakistan? What steps shall taken for capacity building? IRB approval letter of Punjab university is not on IRB letterhead. There is no MTA.

		<ul style="list-style-type: none"> • There is no data sharing agreement document. • There is no mention of study sites from where samples shall be collected with IRB approval in ERC form. • There is no mention of clinical site Co PIs. Clearly mention all the sites as it is written from all over Pakistan. • Budget is not at hand. It is an essential requirement. • Number of samples to be collected is also not mentioned. • The protocol is missing. Also missing is who will be taken as a case of RPL? Which definition will be used. Sample size and how many from different sites is also not found. • Only genetic causes are not responsible for RPL, there are number of other etiological factors. Asking if you have thyroid disorder, is not enough. The other etiological factors especially auto immune disorders need to be ruled out, before genetic cause is being ascertained. In this context mention which tests shall be done and who will pay for it? Provide details of any blood or other tests to be done on parents. • The amount of sample which is required should be mentioned, because the sample needs to be sent for histopathology as well, in order to rule out molar pregnancy. • The consent form is ambiguous, needs to be written, explaining what is being done in easy language. • There is no mention that results will be shared. This is unethical. These subjects are very desperate with repeated pregnancy losses. A misdirected research will make them believe that there is something inherently wrong in their genes, and they can not procreate. The pregnancy rate has been found to be reasonable after RPL. • Psychological counseling may be required but there is no mention of it. There is no mention of how these women shall be treated. • Which of the mutations PI is particularly interested in? • It is also mentioned, there may be change of institution if funding is not secured. • The PI should be suggested to resubmit in light of above comments as at present essential requirements for the evaluation of the proposal are not met.
--	--	--

Title: **AN OPEN LABEL CLINICAL STUDY BCD 248. RELAPSE AND REFRACTORY MULTIPLE MYELOMA.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1214	Dr. Munira Borhany Zia Uddin University Hospital, 4/B, Sharah-e-Ghalib, Block 6, Clifton, Karachi	<ul style="list-style-type: none"> • It is a phase II trial to be conducted at Four sites. Russian Drug. • 21 bullet in IFC is incorrect. The project is being reviewed and not approved yet. • Phase II does not fall under the “treatment” category. Informed consent form give this information which is deceptive. “Phase II clinical trials may also provide more information about the safety of the new treatment and

		<p>how the treatment affects the body”.</p> <ul style="list-style-type: none"> • A 24 page informed consent form is too long plus 5 page bio-sample data. It is mentioned that in Urdu “lamehdood” purpose. It is to be re visited. • It is mentioned that the trial can be stopped any time. What shall be done for the patients in this context? What alternate treatment shall be provided to them? • AKU IRB approval letter is not found. • MTA should be on a legal paper. • DSMB from Pakistan is not found. • Is insurance cover valid for Pakistan? • Data transfer agreement is not found. • Head wise budget and how much amount to be paid to each Co PI is not found. • How much money shall be transferred to KEMU treasury account is also not found. • What is the probable cost of this drug? • Will it be available in future in Pakistan once the study is completed? • What alternate treatment patients shall receive once study is completed? • Is the trial registered in international registry? • What are the other countries in which this trial is currently being carried out? • Share brief results of Phase I trial. • Is the drug approved for use in Russia? If not then The PI at the local hospital should wait for drug approval from Russian authorities. • These are moribund patients, who have failed with multiple drugs in achieving remission, There may be an element of therapeutic misconception. How it will be addressed?
--	--	--



Member Secretary NBC-R



Chairperson NBC-R

Minutes of the NBC-R meeting held on 04-03-2025

The National Bioethics Committee for Research (NBC-R) zoom meeting was held on March 4th, 2025. The following members of NBC-R attended the meeting:

1. Prof. Dr. Saima Pervaiz Iqbal	Chairperson
2. Prof. Dr. Jamshed Akhtar	Member
3. Prof. Dr. Munir Saleemi	Member
4. Prof. Dr. Nazli Hossain	Member
5. Prof. Dr. Marie Andrades	Member
6. Prof. Dr. Saqib Mehmood	Member
7. Prof. Dr. Amjad Mehboob	Member
8. Prof. Dr. Sualeha Siddiq Shekhani	Member
9. Dr. Farkhanda Ghafoor	Member

The following projects reviewed / discussed:

Title: **Leveraging consanguinity in Pakistan to uncover the genomic architecture of Alzheimer's disease: ENIGMA-PAK Feasibility Study.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1215	Prof. Salman Kirmani Department of Pediatrics and Child Health, Aga Khan University, Karachi	<ul style="list-style-type: none"> Please explain the rationale for having more samples from the peri-urban sites rather than the urban site. The questionnaire has been taken directly from the Indian Longitudinal Ageing Survey with terms used commonly in India. It needs a Pakistani context. If a participant screens positive for anxiety or depression or dementia or there is an abnormal MRI to whom will the patient be referred? There is no Urdu informed consent, in addition there is no informed consent for the caregiver. The MTA needs to be drafted onto a legal paper.

Title: **Expired Platelet Concentrates (PCs) for preparation of growth factor richbiologics-Human Platelet Lysate (HPL).**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1217	Dr Raheela Ali Hussaini Blood Bank, Head Office PLOT # ST 02, BLOCK T, QALANDARIA CHOWK, opposite Talib Chaman Park, North Nazimabad Town, Karachi	<ul style="list-style-type: none"> Please explain why this had to come to NBC as this is not a research study but just a transfer of platelet products abroad. What normally happens to expired platelets in blood banks? If China is utilizing these waste products why cannot we do it in Pakistan? What capacity building is there so that Pakistan can develop HPL even if this project is approved? A Material Transfer Agreement needs to be developed on a legal paper.

Title: **Trial: Self-Coping and Resilience in Quality of Life: An RCT of Problem-Solving Therapy for Preventing Recurrence of Myocardial Infarction and Stroke in Haripur, Pakistan.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1218	Dr Shahbaz Ahmed Zakki The University of Haripur near swat chowk Haripur 22620, KPK,	<p>The study duration of 1 year is not sufficient to answer the 3rd objective "To monitor the recurrence of MI and stroke, along with associated risk factors, among the recruited population in Haripur, Pakistan."</p> <ul style="list-style-type: none"> Informed consent needs to be rewritten. No mention of RCT, duration of study and intervention in detail.

		<p>Complete rewrite required</p> <ul style="list-style-type: none"> • For participants in both groups , if severe depression is found what measures will be taken?? Where will they be treated • Some of the questions in the questionnaire do not make sense like asking them the following. They may not know the answers <ul style="list-style-type: none"> ○ What are your most recent physiological measurements? (Please provide values for the following) ○ Blood Pressure: mmHg ○ HDL (Good Cholesterol): mg/dL ○ LDL (Bad Cholesterol): mg/dL ○ Weight: kg ○ Height: cm ○ Blood Glucose mg/dL ○ Other relevant measurements (e.g. BMI, Waist Circumference): • Another question in the questionnaire: Do any of your family members provide you: Social Support Psychological Support No Support. This question is open for interpretation and inappropriate as puts the person in a defensive position • For weight we use KG NOT pounds as mentioned in questionnaire • The questions need to be culturally appropriate. We don't use Shake off the Blues: I felt that I could not shake off the blues even with help from my family or friends.
--	--	---

Next meeting:

The next zoom meeting will be held at 02:30 pm on 18th March, 2025. The following projects will be reviewed:

NBCR-1129 NBCR-1220, NBCR-1221 and NBCR-1222.

Minutes of the NBC-R meeting held on 18-03-2025

The National Bioethics Committee for Research (NBC-R) zoom meeting was held on March 18th, 2025. The following members of NBC-R attended the meeting:

1. Prof. Dr. Saima Pervaiz Iqbal	Chairperson
2. Prof. Dr. Jamshed Akhtar	Member
3. Prof. Dr. Munir Saleemi	Member
4. Prof. Dr. Nazli Hossain	Member
5. Prof. Dr. Saqib Mehmood	Member
6. Prof. Dr. Marie Andrades	Member
7. Prof. Dr. Amjad Mehboob	Member
8. Dr. Farkhanda Ghafoor	Member
9. Dr. Sualeha Siddiq Shekhani	Member

The following projects reviewed / discussed:

Title: **Lu-177 based Synovectomy in the Management of Chronic Inflammatory Joint Diseases.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1129	DR. Aakif Ullah Khan Director & Chief Medical Officer, Institute of Radiotherapy and Nuclear Medicine (IRNUM), Peshawar, Pakistan	<ul style="list-style-type: none"> Clinical Trial Classification: The proposal states that this study is not a clinical trial; however, evaluating the efficacy and safety of Lutetium-177 (Lu-177) compared to established radioisotopes (Yttrium-90 and Rhenium-188) clearly falls under the category of a clinical trial. When a study involves human participants and assesses therapeutic efficacy and safety, it must adhere to clinical trial protocols, including registration and ethical considerations. Study Design: To achieve a proper comparison, the study should include two distinct patient groups: <ul style="list-style-type: none"> One group treated with established isotopes (Yttrium-90 or Rhenium-188). Another group treated with the indigenous Lu-177. This comparative approach will provide credible data on efficacy and safety. Selection of Patients: The inclusion and exclusion criteria for the recruitment of patients is not given. It is crucial that patients are selected carefully, considering factors such as joint condition, previous treatment response, and overall bleeding risk during minor surgical procedures. Moreover, clinicians often consider general health status and comorbidities that could complicate the procedure or recovery process. Patient Information Sheet and Consent Form: In the previous submission, the NBC committee raised concerns about the inadequate patient information sheet and consent form. The revised proposal does not include these essential documents. What is the cost of Lu-177 based RIO? How will efficacy, safety and feasibility be measured? Please clarify your clinical end points. How will side effects be managed? Who will pay for them? Are there any radiation hazards? The aims and objectives read more like a wish list rather than actual measurable objectives. How will patients be recruited? The rationale for radioisotope therapy for hemophilia needs more convincing. Hemophilia is a condition that

		will persist throughout life. Synovectomy will treat the consequence of the disease but not the disease itself.
--	--	---

Title: **Nutritional Supplementation in Pregnancy to Neutralize Heat Stress.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1220	Dr. Junaid Iqbal Department of Paediatrics and Child Health Aga Khan University Karachi	<ul style="list-style-type: none"> Once the study is over and if the supplementation is found to be useful how will it be provided as a post-trial benefit to the involved communities? Will it be affordable for them? Informed consent form needs to mention that even the non-supplementation group will have to provide their samples. Where patients would be referred if they have mental health issues. Is there a mental health expert on board? What is the exact recipe of the nutritional supplement? Will it be socially and culturally acceptable and feasible? Participants in the non-supplemental group may feel disadvantaged. Should they not be provided a standard meal? We would like to see an itemized budget of this project.

Title: **WEIGHT DIVERSE Study: Prevalence of weight related complications across Diverse Weight Classifications – A large cross-sectional study in India, Pakistan, Philippines and Vietnam.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1221	Dr. Abbas Raza: National Hospital, Lahore Dr. Mohammad Ali Arif: Pakistan Institute of Medical Sciences, Islamabad Dr. Amna Subhan: Aga Khan University Hospital, Karachi Dr. Bilal Afzal: Mukhtar A. Sheikh Hospital, Multan Dr. Azizul Hassan Aamir: Peshawar General Hospital, Peshawar	<ul style="list-style-type: none"> Study Approved.

Title: **The Provision of Cardiac Rehabilitation in Pakistan: A National Survey.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1222	Prof. Imran Bashir Chaudhry Suit 201, 2nd floor, Dr. Plaza, do talwar, Clifton, Karachi	<ul style="list-style-type: none"> Please clarify the rationale of this study by an institute that deals with mental health issues and how its results will be useful to Pakistani society. We were surprised that no cardiologists are on board. What is the role of Ziauddin University? Its IRB approval would be required. Please submit an itemized budget with funding source.

Next meeting:

The next zoom meeting will be held at 02:30 pm on 8th April, 2025. The following projects will be reviewed:

NBCR-1223, NBCR-1225 and NBCR-1226.



Member Secretary NBC-R



Chairperson NBC-R

Minutes of the NBC-R meeting held on 08-04-2025

The National Bioethics Committee for Research (NBC-R) zoom meeting was held on April 8th, 2025. The following members of NBC-R attended the meeting:

1. Prof. Dr. Jamshed Akhtar	Chair the Meeting
2. Prof. Dr. Munir Saleemi	Member
3. Prof. Dr. Nazli Hossain	Member
4. Prof. Dr. Amjad Mehboob	Member
5. Prof. Dr. Sualeha Siddiq Shekhani	Member (Sent comments on email)
6. Ms. Tayyaba Rahat	National Coordinator NBC-R
7. Miss. Ayesha Abid	Assistant (NBC-R Secretariat)

The following projects reviewed / discussed:

Title: **“A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobeivibart + Elebsiran Combination Therapy in Participants with Chronic HDV Infection (ECLIPSE 1)”.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1223	Dr. Saeed Hamid Dept of Medicine Aga Khan University, Karachi	<ul style="list-style-type: none">Study Approved.

Title: **Exploring the psychosocial needs of teenage children of parent with breast cancer in a low-middle income country.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1225	Dr. Mueen Abid Pakistan Institute of Living and Learning (PILL) Karachi	<ul style="list-style-type: none">Please elaborate on the rationale of this study. What will this study hope to achieve for the participants?The project mentions that this study is an RCT but it is not in actuality.Please explain the methodology of this study. How will the participants be contacted without feeling that their privacy has been breached?Why has Qambar Shahdad Kot been selected as a study site whereas the study can be completed in any of the big cities?Is there an MoU with PILL and the associated hospitals where data will be collected?Where will the interviews be conducted?Any compensation or token of appreciation to be offered to the participants?Assent form has to be attached.

Title: **Quick Immunization Coverage Survey in High-Risk Districts.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1226	Dr. Sajid Bashir Soofi Dept of Paediatrics, Associate Director Centre of Excellence in Women and Child Health (CoE-WCH), Aga Khan University (AKU), Karachi.	<ul style="list-style-type: none">Please clarify the operational definition of a High Risk District.Please justify the rationale of this study as is it not a routine activity to do a survey after immunizations? What new information is being added by this study?What about safety and security of the investigators especially if they have to collect data from conflict areas like Baluchistan?

Next meeting:

The next zoom meeting will be held at 02:30 pm on 15th April, 2025. The following projects will be reviewed:

NBCR-1227, NBCR-1228 and NBCR-1229.

Minutes of the NBC-R meeting held on 15-04-2025

The National Bioethics Committee for Research (NBC-R) zoom meeting was held on April 15th, 2025. The following members of NBC-R attended the meeting:

1. Prof. Dr. Jamshed Akhtar	Chair the Meeting
2. Prof. Dr. Munir Saleemi	Member
3. Prof. Dr. Nazli Hossain	Member
4. Prof. Dr. Amjad Mehboob	Member
5. Dr. Farkhanda Ghafoor	Member
6. Ms. Tayyaba Rahat	National Coordinator
7. Mr. Waryal Ali Daheri	LDC

The following projects reviewed / discussed:

Title: **Trial: Community-pharmacies managing hypertension: intervention development and evaluation in Bangladesh and Pakistan (COPE-BP).**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1227	Dr. Saima Afaq Institute of Public health and Social Sciences, Khyber Medical University, Peshawar, Pakistan	<ul style="list-style-type: none"> There are five work packages of this proposal. This includes mere interviews to intervention trials. All are grouped at present in one application. This is not appropriate as results of package 1 will inform interventions that are not known at present to be implemented at later stage. Thus PI must de link different packages and submit proposals as separate research protocols. In context of Pakistan what is a community pharmacist? What are their roles and responsibilities and in which part of the KPK they exists / practice and can be verified? A reference and documents may be provided that should cover legal position as well in context of a pharmacist being involved in managing hypertension considering vast geographical context of Pakistan, rural, peri urban and even urban areas where pharmacies are situated in shops and non technical persons running them. DG of concerned department who has endorsed this study may provide evidence in this context. Pharmacists in this proposal are equated to medical doctors. Pharmacists as such are not authorized to recommend any treatment / intervention. They can only carry out the instructions and guide patients about the medicine to be used. At present in which part of KPK medicines are solely dispensed by the pharmacists? What type of collaboration at present exist between doctors and pharmacists? PM &DC issues license to the registered doctors only to practice. This appears to be contradictory to the existing law of Pakistan. This may further add to misconception in minds of ordinary people and confusion may occur between roles of doctors and pharmacists. The curriculum of D Pharm may be shared and pointed out where clinical training is received by them. Is PI currently employed in two different institutions? This is mentioned in CV. This may be explained. Remove NBC address from whom to contact in informed consent form. The IRB approval letter lacks the details of the members and any reference to the meeting where approval was given. Dean name is also mentioned in this document which is not present in IRB form. If he is a co PI then mention his name in the main document. What are the responsibilities of PI in UK and Co PI in Peshawar in context of this study? How on ground they will work?

Title: **Trial: Randomized trial to evaluate and compare the immunogenicity and safety of hexavalent vaccine in healthy infants in a polio-endemic country.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1228	Dr. Ali Faisal Saleem Department of Paediatrics and Child Health, Centre of Excellence – Women & Child Health, 2nd floor Aga Khan University, Stadium Road, Karachi	<ul style="list-style-type: none"> It is suggested to involve relevant government departments at national and provincial level. There is a chance that a study by an individual who is also a member of technical advisory committee at international level may lead to a conflict of interest and by-passing government departments, EPI program lead, may be counterproductive. What is the cost of vaccine? Who will provide it if found useful? Is government of Pakistan not planning to include it in EPI program as it is already in use? This is already in practice in some countries and WHO recommendations are also found. Share AKU IRB approval letter. Share the names of DSMB members. Provide funding approval letter. What shall be amount paid as imbursement for the parents? At least provide a rough number of participants in IRB form that shall be enrolled and from each study site. How PI will tell the communities that they are not part of EPI program and are conducting study on their own? What impact it might cause? Will parents be informed about the results of the study? It is mentioned at a place that shall be shared. Provide details of a need of data sharing and for what purpose. Provide details of how biological samples shall be collected from study sites, stored and transferred to NIH? Who will pay for it? Will results of the study be shared with the parents?

Title: **Association of MiRNA with Cardiometabolic Syndrome for Early Detection and Management.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1229	Prof. Dr. Iram Murtaza Department of Biochemistry, Quaid-i-Azam University, 45320 Islamabad	<ul style="list-style-type: none"> Share the results of previous study done by the PI group and was NBC R approval obtained for that study. There is a difference between objectives and outcomes. At places PI is interested in coronary artery diseases, and other mentions cardiometabolic disorder. This needs clarification. Inclusion criteria also says people without cardiometabolic disorders, how will it be ascertained. Who will be paying for the plethora of tests needed to exclude it? Why women are excluded? They suffer from large number of cardiometabolic disorders too. Settings are unclear, tertiary hospitals of only KPK? Or will it also include other provinces? The PI has not justified the importance of the diagnostic test. The protocol only has 4 references,

		<p>which are a decade old.</p> <ul style="list-style-type: none"> • What will be the utility of the test, in face of rapid testing services currently available. Considering the logistics as has been explained in the protocol. • Will this marker be available in future in Pakistan? Considering decades old data on the subject why it is not translated into the clinical practices yet? • There are a number of flaws in the questionnaire. Even gender is mentioned while women are not included. Diseases are also not clearly defined. • Methods of harvesting blood samples are also incorrect. • Will patients know about the results of the test? • Why RMI is chosen as a study site? • What is included in the management of the patients? Where this management shall be done? • Why study cannot be done in general population? Why it is a hospital based data collection. • How shall results be validated in subjects who are not suffering from any cardiac ailments? • What if positive results are reported? What shall be the strategy from this point onwards? • Where the permanent equipment shall be housed that amount to about 68 lakh rupees? Is this equipment part of already ongoing project of PI which appears similar? • What shall be done with the instrument when study ends? • Will biological samples shall be used for any other purpose?
--	--	---

Next meeting:

The next zoom meeting will be held at 02:30 pm on 22nd April, 2025. The following projects will be reviewed:

NBCR-1231, NBCR-1232 and NBCR-1233.

Minutes of the NBC-R meeting held on 22-04-2025

The National Bioethics Committee for Research (NBC-R) zoom meeting was held on April 22nd, 2025. The following members of NBC-R attended the meeting:

1. Prof. Dr. Saima Pervaiz Iqbal	Chairperson
2. Prof. Dr. Jamshed Akhtar	Member
3. Prof. Dr. Munir Saleemi	Member
4. Prof. Dr. Saqib Mehmood	Member
5. Prof. Dr. Marie Andradess	Member
6. Prof. Dr. Amjad Mehboob	Member
7. Dr. Farkhanda Ghafoor	Member
8. Ms. Tayyaba Rahat	National Coordinator
9. Mr. Waryal Ali Daheri	LDC

The following projects reviewed / discussed:

Title: **An Integrated Approach to Lung Health: Innovations for Vulnerable Populations in Pakistan.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1231	Ms. KINZ UL EMAN, ACCA, MS, MGH, Ph.D (in Progress) House 57 Central Ave, Bahria Town Phase VI Phase 6 Bahria Town, Islamabad	<ul style="list-style-type: none">• These are 5 different projects grouped into one protocol. Each project has a different dimension and needs to be evaluated separately.• A lot of this proposal is theoretical lacking objectivity like where exactly the study will be done, which districts are involved, how will subjects be recruited, how many etc.• With whom will the biological samples be shared with? Are they being sent abroad? If so. data sharing agreement will need to be attached.• Why are pregnant women excluded?• Point 3.5 in informed consent form needs elaboration. Why will the results not be given to the participants?

Title: **xploring the challenges of Polio Eradication in Pakistan..**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1232	Dr. Zubia Mumtaz School of Public Health, University of Alberta 3-309 Edmonton Clinic Health Academy 11405-87 Ave, Edmonton, Canada	<ul style="list-style-type: none">• Study Approved.

Title: **Brain Tumor Registry and Biorepository at Nationwide Children's Hospital.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1233	Dr. Naureen Mushtaq Dept of Oncology Aga Khan University Karachi	<ul style="list-style-type: none">• Study Approved.

Next meeting:

The next zoom meeting will be held at 02:30 pm on 29th April, 2025. The following projects will be reviewed: NBCR-1235, NBCR-1236 and NBCR-1237.

Minutes of the NBC-R meeting held on 29-04-2025

The National Bioethics Committee for Research (NBC-R) zoom meeting was held on April 29th, 2025. The following members of NBC-R attended the meeting:

1. Prof. Dr. Saima Pervaiz Iqbal	Chairperson
2. Prof. Dr. Jamshed Akhtar	Member
3. Prof. Dr. Munir Saleemi	Member
4. Prof. Dr. Saqib Mehmood	Member
5. Prof. Dr. Amjad Mehboob	Member
6. Dr. Farkhanda Ghafoor	Member
7. Ms. Tayyaba Rahat	National Coordinator
8. Ms. Ayesha Abid	Assistant
9. Mr. Waryal Ali Daheri	LDC

The following projects reviewed / discussed:

Title: **To Explore the Transmission Dynamics of HDV Infection and Health Related Quality of Life Assessment in Selected Rural Communities of Sindh, Pakistan.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1235	Dr Ashraf Ali Lakho, FELTP Fellow 15th Cohort, NIH Islamabad	<ul style="list-style-type: none">• Please clarify for us the rationale of this proposal. What are the gaps in knowledge and how will this study help in filling these gaps?• Will HDV positive subjects be given treatment? If yes, by whom?• What is the role of Abbot Pharmaceuticals in this study?• Why is the sample being collected from one district in Sindh?• The informed consent form needs to be in Sindhi.• How is this study aligned with National hepatitis programs?

Title: **Prospective Cohort Comparative-Arm Observational Study to Assess the Impact of a High Fiber Supplement on Lipid Profile in Type 2 Diabetic Patients.**

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1236	Dr. Abbas Raza National Hospital & Medical Center, Street 123, Sector L Dha Phase 1, Lahore Dr Ayesha Nageen Creek General Hospital, Sector 48-H, Creek Road, Sector 48 H Korangi Creek, Karachi,	<ul style="list-style-type: none">• This study is not a cohort study; it is an interventional study and should be designed as such.• Please mention the interventional product and its composition? Have previous studies been done on this product?• Please resubmit the project according to its methodology.

Title: Assessment of Blood Lead Levels in 1-6 years old Children residing in High-risk Areas across Pakistan: Evidence for Policy Action.

Project #	PI Name & Address	Final NBC-R Comments
NBCR-1237	Dr. Mariyam Sarfraz, Associate Professor, Health Services Academy, Islamabad	<ul style="list-style-type: none">• Please clarify the rationale of this project. A lot of things are already known about lead poisoning and how is this aligned with national services.• If a child is determined to have high lead levels, how will this be dealt with?• The questionnaire talks about imported canned food, imported toys whereas in our society there are multifactorial causes of lead poisoning.• What are the potential consequences if a family is known to suffer from high lead levels? What options do they have for retribution? How will water supply and industries come into play?

Next meeting:

The next zoom meeting will be held at 02:30 pm on 6th May, 2025. The following projects will be reviewed: **NBCR-1238, NBCR-1239 and NBCR-1240.**



Member Secretary NBC-R



Chairperson NBC-R